Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson’s disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Journal of Neurology Neurosurgery & Psychiatry

• Publication date

  2006-03-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/jnnp.2005.078659PMID 16543520PMCID PMC2077512
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Long-term benefits in quality of life provided by bilateral subthalamic stimulation in patients with Parkinson disease.

  2005cited by this paper
• Efficacy of deep brain stimulation of the subthalamic nucleus in Parkinson’s disease 4 years after surgery: double blind and open label evaluation

  2004cited by this paper
• Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson's disease

  2004cited by this paper
• Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson's disease: a follow-up of two years.

  2004cited by this paper
• Suicide after successful deep brain stimulation for movement disorders

  2004cited by this paper
• Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson’s disease

  2004cited by this paper
• Switching from ergot to nonergot dopamine agonists in Parkinson's disease: A clinical series and five‐drug dose conversion table

  2004cited by this paper
• Deep brain stimulation of the subthalamic nucleus enhances emotional processing in Parkinson disease.

  2003cited by this paper
• Effects of pallidotomy and bilateral subthalamic stimulation on cognitive function in Parkinson disease

  2003cited by this paper
• Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease.

  2003cited by this paper
• Acute psychotropic effects of bilateral subthalamic nucleus stimulation and levodopa in Parkinson's disease

  2003cited by this paper
• Subthalamic nucleus stimulation affects a frontotemporal network: A PET study

  2003cited by this paper
• [Cost analysis in Italy of various strategies for the treatment of Parkinson disease in the advanced phase].

  2003cited by this paper
• MRI indirect stereotactic targeting for deep brain stimulation in Parkinson's disease.

  2003cited by this paper
• Cognitive and behavioural effects of chronic stimulation of the subthalamic nucleus in patients with Parkinson’s disease

  2003cited by this paper
• Continuous apomorphine infusion and neuropsychiatric disorders: a controlled study in patients with advanced Parkinson’s disease

  2003cited by this paper
• Mania following deep brain stimulation for Parkinson's disease.

  2002cited by this paper
• Behavioural disorders, Parkinson's disease, and subthalamic stimulation

  2002cited by this paper
• Effect on mood of subthalamic DBS for Parkinson’s disease A consecutive series of 24 patients

  2002cited by this paper
• The impact on Parkinson’s disease of electrical parameter settings in STN stimulation

  2002cited by this paper
• Behavioural disorders, Parkinson's disease and subthalamic stimulation

  2002cited by this paper
• Subthalamic nucleus stimulation in Parkinson's disease

  2002cited by this paper
• Aggressive behavior induced by intraoperative stimulation in the triangle of Sano

  2002cited by this paper
• Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: Long‐term follow‐up study of 64 patients

  2002cited by this paper
• Deep brain stimulation of the subthalamic nucleus in Parkinson's disease: comparison of pre- and postoperative neuropsychological evaluation.

  2001cited by this paper
• Influence of chronic bilateral stimulation of the subthalamic nucleus on cognitive function in Parkinson's disease

  2001cited by this paper
• Apomorphine in the Treatment of Parkinson's Disease

  2001cited by this paper
• Neuropsychological outcome of GPi pallidotomy and GPi or STN deep brain stimulation in Parkinson's disease.

  2000cited by this paper
• Neuropsychologic assessment of patients for movement disorder surgery

  2000cited by this paper
• Visual hallucinations induced by deep brain stimulation in Parkinson's disease.

  2000cited by this paper
• Neuropsychological changes between “off” and “on” STN or GPi stimulation in Parkinson’s disease

  2000cited by this paper
• Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies

  2000cited by this paper
• Bilateral subthalamic or pallidal stimulation for Parkinson's disease affects neither memory nor executive functions: A consecutive series of 62 patients

  1999cited by this paper
• Use of apomorphine in parkinsonian patients with neuropsychiatric complications to oral treatment.

  1997cited by this paper
• Subcutaneous apomorphine in parkinsonian on-off oscillations.

  1988cited by this paper

• Curcumin as a potential therapeutic agent for Parkinson’s disease: a systematic review

  2025cites this paper
• Cognitive outcomes of infusion therapies in Parkinson's disease: A comprehensive systematic review.

  2025cites this paper
• Cognitive Outcomes of Advanced Therapies in Parkinson's Disease: A Systematic Review of Apomorphine and Levodopa–Carbidopa Intestinal Gel Therapies

  2025cites this paper
• Invasive therapies for Parkinson’s disease: an adapted excerpt from the guidelines of the German Society of Neurology

  2025cites this paper
• Real-world experience with continuous subcutaneous foslevodopa/foscarbidopa infusion: insights and recommendations

  2025cites this paper
• Influence of continuous subcutaneous apomorphine infusion on cognition and behavior in Parkinson's disease: A systematic review.

  2024cites this paper
• Continuous Subcutaneous Infusion Delivery of Apomorphine in Parkinson's Disease: A Systematic Review

  2023cites this paper
• Neurobiology of Depression in Parkinson's disease: Insights into Epidemiology, Molecular Mechanisms and Treatment Strategies.

  2023cites this paper
• Leczenie zaawansowanej choroby Parkinsona — rekomendacje Polskiego Towarzystwa Choroby Parkinsona i Innych Zaburzeń Ruchowych

  2022cites this paper
• Deep brain stimulation in Parkinson's disease: analysis of brain fractional anisotropy differences in operated patients.

  2022cites this paper
• A Review on Response to Device-Aided Therapies Used in Monogenic Parkinsonism and GBA Variants Carriers: A Need for Guidelines and Comparative Studies

  2022cites this paper
• Why do ‘OFF’ periods still occur during continuous drug delivery in Parkinson’s disease?

  2022cites this paper
• Efficacy and safety of apomorphine pump infusion in Filipino patients insufficiently controlled on oral anti-Parkinson medications: an open-label, pilot study

  2022cites this paper
• Short and Long-Term Cognitive Effects of Subthalamic Deep Brain Stimulation in Parkinson’s Disease and Identification of Relevant Factors

  2022cites this paper
• Continuous Subcutaneous Apomorphine Infusion before Subthalamic Deep Brain Stimulation: A Prospective, Comparative Study in 20 Patients

  2021cites this paper
• Continuous Subcutaneous Apomorphine Infusion in Advanced Parkinson’s Disease: A Systematic Review

  2021influential citation
• Translating Evidence to Advanced Parkinson's Disease Patients: A Systematic Review and Meta‐Analysis

  2021cites this paper
• Cognitive outcome following bilateral subthalamic nucleus deep brain stimulation for Parkinson’s disease—a comparative observational study in Indian patients

  2021cites this paper
• Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson’s Disease: A Meta-Analysis of Mood Effects

  2021cites this paper
• Orientation selective deep brain stimulation of the subthalamic nucleus in rats

  2020cites this paper
• Use of high-density EEG in patients with Parkinson's disease treated with deep brain stimulation.

  2020cites this paper
• The effect of STN DBS on modulating brain oscillations: consequences for motor and cognitive behavior

  2020cites this paper
• Safety considerations when using non-ergot dopamine agonists to treat Parkinson’s disease

  2020cites this paper
• Predictive Factors of Antiparkinsonian Drug Reduction after Subthalamic Stimulation for Parkinson’s Disease

  2019cites this paper
• Continuous subcutaneous apomorphine infusion in Parkinson’s disease: causes of discontinuation and subsequent treatment strategies

  2019cites this paper
• EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson's disease

  2019cites this paper
• The next chapter in symptomatic Parkinson disease treatments.

  2019cites this paper
• Analyzing Apomorphine-Mediated Effects in a Cell Model for Parkinson's Disease with Partial Least Squares Structure Equation Modeling

  2019cites this paper
• Continuous subcutaneous apomorphine in advanced Parkinson’s disease patients treated with deep brain stimulation

  2019cites this paper
• A Review of Cognitive Outcomes Across Movement Disorder Patients Undergoing Deep Brain Stimulation

  2019cites this paper
• Deep Brain Stimulation in Parkinson's Disease

  2018cites this paper
• Rationale and patient selection for interventional therapies in Parkinson’s disease

  2018cites this paper
• On the Use of t-Distributed Stochastic Neighbor Embedding for Data Visualization and Classification of Individuals with Parkinson's Disease

  2018cites this paper
• İleri Evre Parkinson Hastalığında Subkutan Apomorfin Klinik Deneyimlerimiz

  2018cites this paper
• Effects of deep brain stimulation of the subthalamic nucleus and the pedunculopontine nucleus on cognitive function in Parkinson's disease

  2018cites this paper
• Continuous subcutaneous apomorphine infusion does not impair the dynamics of cognitive action control in mild to moderate Parkinson’s disease

  2018influential citation
• Effects of continuous subcutaneous apomorphine infusion in Parkinson's disease without cognitive impairment on motor, cognitive, psychiatric symptoms and quality of life.

  2018cites this paper
• Update zur intensivierten Therapie des fortgeschrittenen idiopathischen Parkinson-Syndroms

  2017cites this paper
• Apomorphine-induced pathway perturbation in MPP + -treated SH-SY5Y cells

  2017cites this paper
• [Practical use of continuous apomorphine infusion via pump].

  2017cites this paper
• Cognitive Impact of Deep Brain Stimulation on Parkinson's Disease Patients

  2017influential citation
• Continuous subcutaneous apomorphine infusion in advanced Parkinson’s disease: 10-year experience with 230 patients

  2017cites this paper
• Device-Aided Treatment Strategies in Advanced Parkinson's Disease.

  2017cites this paper
• Continuous subcutaneous apomorphine infusion in Parkinson's disease patients with cognitive dysfunction: A retrospective long-term follow-up study.

  2017cites this paper
• Infusion treatments and deep brain stimulation in Parkinson's Disease: The role of nursing.

  2016cites this paper
• Apomorphine - pharmacological properties and clinical trials in Parkinson's disease.

  2016cites this paper
• Parkinsonism and Related Disorders

  2016cites this paper
• The efficacy of apomorphine - A non-motor perspective.

  2016cites this paper
• Deep Brain Stimulation for Parkinson’s Disease with Early Motor Complications: A UK Cost-Effectiveness Analysis

  2016cites this paper
• Eskalationstherapien bei Morbus Parkinson

  2016cites this paper
• Feature visualization and classification for the discrimination between individuals with Parkinson’s disease under levodopa and DBS treatments

  2016cites this paper
• Genome-wide transcriptional response of MPP+-treated human neuroblastoma SH-SY5Y cells to apomorphine

  2016cites this paper
• Neuroprotective and Therapeutic Strategies against Parkinson’s Disease: Recent Perspectives

  2016cites this paper
• [Current possibilities of quality of life improvement in the late stages of Parkinson's disease].

  2015cites this paper
• Therapeutic strategies to prevent and manage dyskinesias in Parkinson’s disease

  2015cites this paper
• [Current possibilities of quality of life improvement in the late stages of Parkinson's disease].

  2015cites this paper
• Letter to the editor Reply: Re: Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson’s Disease in the UK and Germany

  2015cites this paper
• Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease--Clinical practice recommendations.

  2015cites this paper
• Levodopa/carbidopa intestinal gel: an effective formulation for the management of advanced Parkinson's disease

  2015cites this paper
• Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson’s disease in the UK and Germany

  2015cites this paper
• Effective Delivery of Apomorphine in the Management of Parkinson Disease: Practical Considerations for Clinicians and Parkinson Nurses

  2015cites this paper
• Particularités gériatriques de la maladie de Parkinson : aspects cliniques et thérapeutiques

  2015cites this paper
• Deep brain stimulation and cognitive decline in Parkinson’s disease: The predictive value of electroencephalography

  2015cites this paper
• [Geriatric particularities of Parkinson's disease: Clinical and therapeutic aspects].

  2015cites this paper
• Die kontinuierliche subkutane Apomorphingabe

  2015cites this paper
• Cognition and Neuropsychiatric Symptoms

  2014cites this paper
• Pharmacological Treatment Options for Levodopa-Induced Dyskinesia

  2014cites this paper
• Twenty Years of Apomorphine Therapy - How Does it Compare with Levodopa? Highlights of a Satellite Symposium Held at the 18th International Congress of Parkinson's Disease and Movement Disorders, Stockholm, 8-12 June 2014

  2014cites this paper
• Cognitive Changes after Deep Brain Stimulation in Parkinson's Disease: A Critical Review

  2014cites this paper
• Dopamine receptor agonists for Parkinson's disease

  2014cites this paper
• Clinical insights into use of apomorphine in Parkinson's disease: tools for clinicians.

  2014cites this paper
• The role of subcutaneous infusion of apomorphine in Parkinson’s disease

  2014cites this paper
• Treatment of advanced Parkinson's disease.

  2014cites this paper
• Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson'd Disease: Final 12-Month, Open-Label Results

  2014cites this paper
• New Clinical Trials for Levodopa-Induced Dyskinesia

  2014cites this paper
• Treatment of motor fluctuations in Parkinson’s disease: recent developments and future directions

  2014cites this paper
• Subcutaneous infusions of apomorphine: a reappraisal of its therapeutic efficacy in advanced Parkinson’s disease

  2013cites this paper
• Advanced Parkinson's disease: clinical characteristics and treatment. Part II.

  2013cites this paper
• Dopamine-transporter levels drive striatal responses to apomorphine in Parkinson's disease

  2013cites this paper
• Selecting deep brain stimulation or infusion therapies in advanced Parkinson’s disease: an evidence-based review

  2013cites this paper
• Validity and feasibility of best worst scaling using multiple treatment outcomes of Parkinson's disease

  2013cites this paper
• [Prevalence and main methods of treatment of advanced stages of Parkinson's disease].

  2013cites this paper
• Apomorfina w zaawansowanej chorobie Parkinsona

  2013influential citation
• [Apomorphine in advanced Parkinson disease].

  2013cites this paper
• Consensus statementAdvanced Parkinson's disease: Clinical characteristics and treatment. Part IIEnfermedad de Parkinson avanzada. Características clínicas y tratamiento. Parte II☆

  2013cites this paper
• Optogenetic cell control in experimental models of neurological disorders.

  2013cites this paper
• Subcutaneous apomorphine and non-motor symptoms in Parkinson's disease.

  2013cites this paper
• Peripheral neuropathy in Parkinson's disease: levodopa exposure and implications for duodenal delivery.

  2013cites this paper
• [The concept of continuous dopaminergic stimulation in the treatment of late stages of Parkinson's disease].

  2013cites this paper
• Eskalationstherapie mit Hirnstimulation und Medikamentenpumpen

  2013cites this paper
• Advanced Parkinson's disease: Clinical characteristics and treatment. Part II

  2013cites this paper
• [Limits of conventional oral and transdermal medication in Parkinson's disease].

  2012cites this paper
• The Pharmacological Properties and Therapeutic Use of Apomorphine

  2012cites this paper
• Apomorphine infusion in advanced Parkinson's patients with subthalamic stimulation contraindications.

  2012influential citation
• Nonmotor outcomes in Parkinson’s disease: is deep brain stimulation better than dopamine replacement therapy?

  2012cites this paper
• Drug therapy in patients with Parkinson’s disease

  2012cites this paper
• Parkinson's Disease Therapeutics: New Developments and Challenges Since the Introduction of Levodopa

  2012cites this paper
• [Candidate patient for treatment with continuous apomorphine infusion].

  2012cites this paper
• [Parkinson's disease: current standards in diagnostics and therapy].

  2012cites this paper
• [Subcutaneous continuous apomorphine infusion: treatment initiation and follow up].

  2012cites this paper